<DOC>
	<DOCNO>NCT02182830</DOCNO>
	<brief_summary>This trial design investigate efficacy safety empagliflozin compare placebo hypertensive black/African Americans type 2 Diabetes Mellitus . Since hyperglycaemia hypertension key risk factor micro- macrovascular complication , assessment glucose BP lower effect empagliflozin hypertensive African American patient type 2 Diabetes Mellitus could provide clinically highly relevant , new information use empagliflozin . Essential hypertension four time common African Americans Caucasians . One risk factor hypertension sodium sensitivity approximately one third essential hypertensive population responsive sodium intake . There high association hypertension sodium sensitivity African American patient type 2 Diabetes Mellitus . The treatment duration trial ( 24 week ) enable assessment clinically relevant endpoint decrease HbA1c , well accepted measurement chronic glycaemic control key secondary endpoint decrease systolic BP ( SBP ) diastolic BP ( DBP ) 12 24 week .</brief_summary>
	<brief_title>24 Week Efficacy Safety Study Empagliflozin ( BI 10773 ) Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis Type 2 Diabetes Mellitus ( T2DM ) prior inform consent . Male female black/African American patient diet exercise regimen EITHER drugnaïve ( define absence oral antidiabetic therapy , glucagon like peptide1 ( GLP1 ) analog insulin 12 week , 16 week pioglitazone prior randomisation ) OR pretreated stable dose Metformin , Sulfonylurea , Dipeptidyl peptidase4 ( DPP4 ) inhibitor , metformin plus sulfonylurea , metformin plus DPP4 inhibitor . Treatment unchanged minimum 12 week prior randomization . Dose metformin : maximum tolerate dose The maximum daily dose Sulfonylurea ( SU ) DPP4 inhibitor exceed state local label . HbA1c &gt; = 7.0 % ( 53 mmol/mol ) ≤ 11.0 % ( 97 mmol/mol ) Visit 1 ( screen ) . Mean seat Systolic Blood Pressure ( SBP ) 140180 mmHg Visit 1 ( screen ) . Successful completion baseline Ambulatory Blood Pressure Monitor ( ABPM ) test mean SBP 135175 mmHg prior randomisation . Treatment stable dos least one 4 antihypertensive medication &gt; = 4 week prior randomisation . Age &gt; = 18 year Visit 1 ( screen ) Signed date write informed consent date Visit 1 accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : Uncontrolled hyperglycemia glucose level &gt; 270 mg/dl ( &gt; 15.0 mmol/L ) overnight fast placebo runin ( include Visit 2.1 ) confirm second measurement ( day ) . Exposure antidiabetic medication within 12 week prior randomisation metformin , sulfonylurea , Dipeptidyl peptidase4 ( DPP4 ) inhibitor , metformin plus sulfonylurea metformin plus DPP4 inhibitor . Current hypertension treatment oral Minoxidil ( topical minoxidil hair growth allow ) . Mean seat Systolic Blood Pressure ( SBP ) ≥181 mmHg placebo runin visit confirm second measurement ( day ) preferably within one day . Upper arm circumference exceed upper circumference level cuff size either Ambulatory Blood Pressure Monitor ( ABPM ) and/or ( BP ) measurement device use study . Night shift worker routinely sleep daytime and/or whose work hour include midnight . Diagnosis autoimmune diabetes/Type I diabetes mellitus , monogenic ( neonatal maturity onset diabetes young ( MODY ) ) diabetes Type I diabetes adults/latent autoimmune diabetes adult ( LADA ) per investigator patient medical historyat time Visit 1 ( screen ) . Known suspected secondary hypertension ( e.g . renal artery stenosis , phaeochromocytoma , Cushing 's disease ) . History evidence hypertensive retinopathy ( KeithWagener grade III IV ) and/orhypertensive encephalopathy . Clinically significant valvular heart disease severe aortic stenosis opinion theinvestigator . Acute coronary syndrome ( non ST wave elevate myocardial infarction ( STEMI ) , STEMI unstable angina pectoris ) , stroke transient ischemic attack within 3 month prior inform consent . Indication liver disease , define serum level either Alanine Aminotransferase ( ALT ) ( Serum Glutamic Pyruvate Transaminase ( SGPT ) ) , Aspartate Aminotransferase ( AST ) ( Serum Glutamic Oxaloacetic Transaminase ( SGOT ) ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine screen and/or runin phase . Impaired renal function , define Estimated Glomerular Filtration Rate ( eGFR ) &lt; 45 ml/min/1.73m2 ( moderate renal impairment , chronic kidney disease epidemiology collaboration Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) formula ) determine screen and/or runin phase . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year . Blood dyscrasia disorder cause hemolysis unstable Red Blood Cells ( e.g . malaria , babesiosis , haemolytic anaemia , thalassemia , sickle cell anaemia ( sickle cell trait allow ) ) . Medical history sign symptom diabetic autonomic neuropathy . Treatment antiobesity drug 3 month prior randomisation ( i.e . surgery , aggressive diet regimen , etc . ) lead unstable body weight . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except Type 2 Diabetes Mellitus ( T2DM ) opinion investigator . Premenopausal woman ( last menstruation &lt; =1 year prior informed consent ) : nursing pregnant childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , completesexual abstinence ( acceptable local authority ) , double barrier method vasectomise partner . Alcohol , drug confectionary liquorice abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake investigator 's opinion . Intake investigational drug another trial within 30 day prior intake study medication trial ; participate another trial ( involve investigational drug and/or followup ) discontinue medication trial . Any clinical condition would jeopardize patient 's safety participate clinical trial opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>